Anti-Infective Endotracheal Tube
The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More
Global Antihypertensive Market Research Report 2023
1 Antihypertensive Market Overview
1.1 Product Overview and Scope of Antihypertensive
1.2 Antihypertensive Segment by Type
1.2.1 Global Antihypertensive Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Diuretics
1.2.3 Angiotensin Converting Enzyme (ACE) Inhibitors
1.2.4 Angiotensin Receptor Blockers (ARBs)
1.2.5 Calcium Channel Blockers
1.2.6 Beta Blockers
1.2.7 Alpha Blockers
1.2.8 Vasodilators & Renin Inhibitors
1.3 Antihypertensive Segment by Application
1.3.1 Global Antihypertensive Sales Comparison by Application: (2022-2028)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Global Antihypertensive Market Size Estimates and Forecasts
1.4.1 Global Antihypertensive Revenue 2017-2028
1.4.2 Global Antihypertensive Sales 2017-2028
1.4.3 Antihypertensive Market Size by Region: 2017 Versus 2021 Versus 2028
2 Antihypertensive Market Competition by Manufacturers
2.1 Global Antihypertensive Sales Market Share by Manufacturers (2017-2022)
2.2 Global Antihypertensive Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Antihypertensive Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Antihypertensive Manufacturing Sites, Area Served, Product Type
2.5 Antihypertensive Market Competitive Situation and Trends
2.5.1 Antihypertensive Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Antihypertensive Players Market Share by Revenue
2.5.3 Global Antihypertensive Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antihypertensive Retrospective Market Scenario by Region
3.1 Global Antihypertensive Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Antihypertensive Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Antihypertensive Market Facts & Figures by Country
3.3.1 North America Antihypertensive Sales by Country
3.3.2 North America Antihypertensive Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Antihypertensive Market Facts & Figures by Country
3.4.1 Europe Antihypertensive Sales by Country
3.4.2 Europe Antihypertensive Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Antihypertensive Market Facts & Figures by Region
3.5.1 Asia Pacific Antihypertensive Sales by Region
3.5.2 Asia Pacific Antihypertensive Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Antihypertensive Market Facts & Figures by Country
3.6.1 Latin America Antihypertensive Sales by Country
3.6.2 Latin America Antihypertensive Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Antihypertensive Market Facts & Figures by Country
3.7.1 Middle East and Africa Antihypertensive Sales by Country
3.7.2 Middle East and Africa Antihypertensive Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Antihypertensive Historic Market Analysis by Type
4.1 Global Antihypertensive Sales Market Share by Type (2017-2022)
4.2 Global Antihypertensive Revenue Market Share by Type (2017-2022)
4.3 Global Antihypertensive Price by Type (2017-2022)
5 Global Antihypertensive Historic Market Analysis by Application
5.1 Global Antihypertensive Sales Market Share by Application (2017-2022)
5.2 Global Antihypertensive Revenue Market Share by Application (2017-2022)
5.3 Global Antihypertensive Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Pfizer Antihypertensive Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Norvatis
6.2.1 Norvatis Corporation Information
6.2.2 Norvatis Description and Business Overview
6.2.3 Norvatis Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Norvatis Antihypertensive Product Portfolio
6.2.5 Norvatis Recent Developments/Updates
6.3 Merck & Co.
6.3.1 Merck & Co. Corporation Information
6.3.2 Merck & Co. Description and Business Overview
6.3.3 Merck & Co. Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Merck & Co. Antihypertensive Product Portfolio
6.3.5 Merck & Co. Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Sanofi Antihypertensive Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Corporation Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.5.4 AstraZeneca Antihypertensive Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 GSK
6.6.1 GSK Corporation Information
6.6.2 GSK Description and Business Overview
6.6.3 GSK Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.6.4 GSK Antihypertensive Product Portfolio
6.6.5 GSK Recent Developments/Updates
6.7 Daiichi-Sankyo
6.6.1 Daiichi-Sankyo Corporation Information
6.6.2 Daiichi-Sankyo Description and Business Overview
6.6.3 Daiichi-Sankyo Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Daiichi-Sankyo Antihypertensive Product Portfolio
6.7.5 Daiichi-Sankyo Recent Developments/Updates
6.8 Boehringer-Ingelheim
6.8.1 Boehringer-Ingelheim Corporation Information
6.8.2 Boehringer-Ingelheim Description and Business Overview
6.8.3 Boehringer-Ingelheim Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Boehringer-Ingelheim Antihypertensive Product Portfolio
6.8.5 Boehringer-Ingelheim Recent Developments/Updates
6.9 Bayer
6.9.1 Bayer Corporation Information
6.9.2 Bayer Description and Business Overview
6.9.3 Bayer Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Bayer Antihypertensive Product Portfolio
6.9.5 Bayer Recent Developments/Updates
6.10 Johnson & Johnson
6.10.1 Johnson & Johnson Corporation Information
6.10.2 Johnson & Johnson Description and Business Overview
6.10.3 Johnson & Johnson Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Johnson & Johnson Antihypertensive Product Portfolio
6.10.5 Johnson & Johnson Recent Developments/Updates
6.11 Bristol-Myers Squibb
6.11.1 Bristol-Myers Squibb Corporation Information
6.11.2 Bristol-Myers Squibb Antihypertensive Description and Business Overview
6.11.3 Bristol-Myers Squibb Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Bristol-Myers Squibb Antihypertensive Product Portfolio
6.11.5 Bristol-Myers Squibb Recent Developments/Updates
6.12 Tekeda
6.12.1 Tekeda Corporation Information
6.12.2 Tekeda Antihypertensive Description and Business Overview
6.12.3 Tekeda Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Tekeda Antihypertensive Product Portfolio
6.12.5 Tekeda Recent Developments/Updates
6.13 Ranbaxy Laboratories
6.13.1 Ranbaxy Laboratories Corporation Information
6.13.2 Ranbaxy Laboratories Antihypertensive Description and Business Overview
6.13.3 Ranbaxy Laboratories Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Ranbaxy Laboratories Antihypertensive Product Portfolio
6.13.5 Ranbaxy Laboratories Recent Developments/Updates
6.14 Shihuida Pharm
6.14.1 Shihuida Pharm Corporation Information
6.14.2 Shihuida Pharm Antihypertensive Description and Business Overview
6.14.3 Shihuida Pharm Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Shihuida Pharm Antihypertensive Product Portfolio
6.14.5 Shihuida Pharm Recent Developments/Updates
6.15 Second Pharmaceutical
6.15.1 Second Pharmaceutical Corporation Information
6.15.2 Second Pharmaceutical Antihypertensive Description and Business Overview
6.15.3 Second Pharmaceutical Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Second Pharmaceutical Antihypertensive Product Portfolio
6.15.5 Second Pharmaceutical Recent Developments/Updates
6.16 Lupin Limited.
6.16.1 Lupin Limited. Corporation Information
6.16.2 Lupin Limited. Antihypertensive Description and Business Overview
6.16.3 Lupin Limited. Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Lupin Limited. Antihypertensive Product Portfolio
6.16.5 Lupin Limited. Recent Developments/Updates
6.17 Yangtze River Pharmaceutical
6.17.1 Yangtze River Pharmaceutical Corporation Information
6.17.2 Yangtze River Pharmaceutical Antihypertensive Description and Business Overview
6.17.3 Yangtze River Pharmaceutical Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Yangtze River Pharmaceutical Antihypertensive Product Portfolio
6.17.5 Yangtze River Pharmaceutical Recent Developments/Updates
6.18 Hengrui Medicine
6.18.1 Hengrui Medicine Corporation Information
6.18.2 Hengrui Medicine Antihypertensive Description and Business Overview
6.18.3 Hengrui Medicine Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Hengrui Medicine Antihypertensive Product Portfolio
6.18.5 Hengrui Medicine Recent Developments/Updates
6.19 Qilu Pharmaceutical
6.19.1 Qilu Pharmaceutical Corporation Information
6.19.2 Qilu Pharmaceutical Antihypertensive Description and Business Overview
6.19.3 Qilu Pharmaceutical Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Qilu Pharmaceutical Antihypertensive Product Portfolio
6.19.5 Qilu Pharmaceutical Recent Developments/Updates
6.20 HUALON
6.20.1 HUALON Corporation Information
6.20.2 HUALON Antihypertensive Description and Business Overview
6.20.3 HUALON Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.20.4 HUALON Antihypertensive Product Portfolio
6.20.5 HUALON Recent Developments/Updates
6.21 Dawnrays
6.21.1 Dawnrays Corporation Information
6.21.2 Dawnrays Antihypertensive Description and Business Overview
6.21.3 Dawnrays Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.21.4 Dawnrays Antihypertensive Product Portfolio
6.21.5 Dawnrays Recent Developments/Updates
6.22 HISUN Pharmceutical
6.22.1 HISUN Pharmceutical Corporation Information
6.22.2 HISUN Pharmceutical Antihypertensive Description and Business Overview
6.22.3 HISUN Pharmceutical Antihypertensive Sales, Revenue and Gross Margin (2017-2022)
6.22.4 HISUN Pharmceutical Antihypertensive Product Portfolio
6.22.5 HISUN Pharmceutical Recent Developments/Updates
7 Antihypertensive Manufacturing Cost Analysis
7.1 Antihypertensive Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Antihypertensive
7.4 Antihypertensive Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Antihypertensive Distributors List
8.3 Antihypertensive Customers
9 Antihypertensive Market Dynamics
9.1 Antihypertensive Industry Trends
9.2 Antihypertensive Market Drivers
9.3 Antihypertensive Market Challenges
9.4 Antihypertensive Market Restraints
10 Global Market Forecast
10.1 Antihypertensive Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Antihypertensive by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Antihypertensive by Type (2023-2028)
10.2 Antihypertensive Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Antihypertensive by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Antihypertensive by Application (2023-2028)
10.3 Antihypertensive Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Antihypertensive by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Antihypertensive by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Antihypertensive Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Antihypertensive Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Antihypertensive Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Antihypertensive Market Competitive Situation by Manufacturers in 2021
Table 5. Global Antihypertensive Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Antihypertensive Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Antihypertensive Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Antihypertensive Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Antihypertensive Average Price (USD/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Antihypertensive Manufacturing Sites and Area Served
Table 11. Manufacturers Antihypertensive Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Antihypertensive by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antihypertensive as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Antihypertensive Sales by Region (2017-2022) & (K Units)
Table 16. Global Antihypertensive Sales Market Share by Region (2017-2022)
Table 17. Global Antihypertensive Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Antihypertensive Revenue Market Share by Region (2017-2022)
Table 19. North America Antihypertensive Sales by Country (2017-2022) & (K Units)
Table 20. North America Antihypertensive Sales Market Share by Country (2017-2022)
Table 21. North America Antihypertensive Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Antihypertensive Revenue Market Share by Country (2017-2022)
Table 23. Europe Antihypertensive Sales by Country (2017-2022) & (K Units)
Table 24. Europe Antihypertensive Sales Market Share by Country (2017-2022)
Table 25. Europe Antihypertensive Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Antihypertensive Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Antihypertensive Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Antihypertensive Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Antihypertensive Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Antihypertensive Revenue Market Share by Region (2017-2022)
Table 31. Latin America Antihypertensive Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Antihypertensive Sales Market Share by Country (2017-2022)
Table 33. Latin America Antihypertensive Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Antihypertensive Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Antihypertensive Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Antihypertensive Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Antihypertensive Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Antihypertensive Revenue Market Share by Country (2017-2022)
Table 39. Global Antihypertensive Sales by Type (2017-2022) & (K Units)
Table 40. Global Antihypertensive Sales Market Share by Type (2017-2022)
Table 41. Global Antihypertensive Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Antihypertensive Revenue Share by Type (2017-2022)
Table 43. Global Antihypertensive Price by Type (2017-2022) & (USD/Unit)
Table 44. Global Antihypertensive Sales (K Units) by Application (2017-2022)
Table 45. Global Antihypertensive Sales Market Share by Application (2017-2022)
Table 46. Global Antihypertensive Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Antihypertensive Revenue Share by Application (2017-2022)
Table 48. Global Antihypertensive Price by Application (2017-2022) & (USD/Unit)
Table 49. Pfizer Corporation Information
Table 50. Pfizer Description and Business Overview
Table 51. Pfizer Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 52. Pfizer Antihypertensive Product
Table 53. Pfizer Recent Developments/Updates
Table 54. Norvatis Corporation Information
Table 55. Norvatis Description and Business Overview
Table 56. Norvatis Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 57. Norvatis Antihypertensive Product
Table 58. Norvatis Recent Developments/Updates
Table 59. Merck & Co. Corporation Information
Table 60. Merck & Co. Description and Business Overview
Table 61. Merck & Co. Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 62. Merck & Co. Antihypertensive Product
Table 63. Merck & Co. Recent Developments/Updates
Table 64. Sanofi Corporation Information
Table 65. Sanofi Description and Business Overview
Table 66. Sanofi Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 67. Sanofi Antihypertensive Product
Table 68. Sanofi Recent Developments/Updates
Table 69. AstraZeneca Corporation Information
Table 70. AstraZeneca Description and Business Overview
Table 71. AstraZeneca Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 72. AstraZeneca Antihypertensive Product
Table 73. AstraZeneca Recent Developments/Updates
Table 74. GSK Corporation Information
Table 75. GSK Description and Business Overview
Table 76. GSK Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 77. GSK Antihypertensive Product
Table 78. GSK Recent Developments/Updates
Table 79. Daiichi-Sankyo Corporation Information
Table 80. Daiichi-Sankyo Description and Business Overview
Table 81. Daiichi-Sankyo Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 82. Daiichi-Sankyo Antihypertensive Product
Table 83. Daiichi-Sankyo Recent Developments/Updates
Table 84. Boehringer-Ingelheim Corporation Information
Table 85. Boehringer-Ingelheim Description and Business Overview
Table 86. Boehringer-Ingelheim Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 87. Boehringer-Ingelheim Antihypertensive Product
Table 88. Boehringer-Ingelheim Recent Developments/Updates
Table 89. Bayer Corporation Information
Table 90. Bayer Description and Business Overview
Table 91. Bayer Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 92. Bayer Antihypertensive Product
Table 93. Bayer Recent Developments/Updates
Table 94. Johnson & Johnson Corporation Information
Table 95. Johnson & Johnson Description and Business Overview
Table 96. Johnson & Johnson Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 97. Johnson & Johnson Antihypertensive Product
Table 98. Johnson & Johnson Recent Developments/Updates
Table 99. Bristol-Myers Squibb Corporation Information
Table 100. Bristol-Myers Squibb Description and Business Overview
Table 101. Bristol-Myers Squibb Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 102. Bristol-Myers Squibb Antihypertensive Product
Table 103. Bristol-Myers Squibb Recent Developments/Updates
Table 104. Tekeda Corporation Information
Table 105. Tekeda Description and Business Overview
Table 106. Tekeda Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 107. Tekeda Antihypertensive Product
Table 108. Tekeda Recent Developments/Updates
Table 109. Ranbaxy Laboratories Corporation Information
Table 110. Ranbaxy Laboratories Description and Business Overview
Table 111. Ranbaxy Laboratories Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 112. Ranbaxy Laboratories Antihypertensive Product
Table 113. Ranbaxy Laboratories Recent Developments/Updates
Table 114. Shihuida Pharm Corporation Information
Table 115. Shihuida Pharm Description and Business Overview
Table 116. Shihuida Pharm Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 117. Shihuida Pharm Antihypertensive Product
Table 118. Shihuida Pharm Recent Developments/Updates
Table 119. Second Pharmaceutical Corporation Information
Table 120. Second Pharmaceutical Description and Business Overview
Table 121. Second Pharmaceutical Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 122. Second Pharmaceutical Antihypertensive Product
Table 123. Second Pharmaceutical Recent Developments/Updates
Table 124. Lupin Limited. Corporation Information
Table 125. Lupin Limited. Description and Business Overview
Table 126. Lupin Limited. Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 127. Lupin Limited. Antihypertensive Product
Table 128. Lupin Limited. Recent Developments/Updates
Table 129. Yangtze River Pharmaceutical Corporation Information
Table 130. Yangtze River Pharmaceutical Description and Business Overview
Table 131. Yangtze River Pharmaceutical Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 132. Yangtze River Pharmaceutical Antihypertensive Product
Table 133. Yangtze River Pharmaceutical Recent Developments/Updates
Table 134. Hengrui Medicine Corporation Information
Table 135. Hengrui Medicine Description and Business Overview
Table 136. Hengrui Medicine Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 137. Hengrui Medicine Antihypertensive Product
Table 138. Hengrui Medicine Recent Developments/Updates
Table 139. Qilu Pharmaceutical Corporation Information
Table 140. Qilu Pharmaceutical Description and Business Overview
Table 141. Qilu Pharmaceutical Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 142. Qilu Pharmaceutical Antihypertensive Product
Table 143. Qilu Pharmaceutical Recent Developments/Updates
Table 144. HUALON Corporation Information
Table 145. HUALON Description and Business Overview
Table 146. HUALON Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 147. HUALON Antihypertensive Product
Table 148. HUALON Recent Developments/Updates
Table 149. Dawnrays Corporation Information
Table 150. Dawnrays Description and Business Overview
Table 151. Dawnrays Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 152. Dawnrays Antihypertensive Product
Table 153. Dawnrays Recent Developments/Updates
Table 154. HISUN Pharmceutical Corporation Information
Table 155. HISUN Pharmceutical Description and Business Overview
Table 156. HISUN Pharmceutical Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 157. HISUN Pharmceutical Antihypertensive Product
Table 158. HISUN Pharmceutical Recent Developments/Updates
Table 159. Production Base and Market Concentration Rate of Raw Material
Table 160. Key Suppliers of Raw Materials
Table 161. Antihypertensive Distributors List
Table 162. Antihypertensive Customers List
Table 163. Antihypertensive Market Trends
Table 164. Antihypertensive Market Drivers
Table 165. Antihypertensive Market Challenges
Table 166. Antihypertensive Market Restraints
Table 167. Global Antihypertensive Sales Forecast by Type (2023-2028) & (K Units)
Table 168. Global Antihypertensive Sales Market Share Forecast by Type (2023-2028)
Table 169. Global Antihypertensive Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 170. Global Antihypertensive Revenue Market Share Forecast by Type (2023-2028)
Table 171. Global Antihypertensive Sales Forecast by Application (2023-2028) & (K Units)
Table 172. Global Antihypertensive Sales Market Share Forecast by Application (2023-2028)
Table 173. Global Antihypertensive Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 174. Global Antihypertensive Revenue Market Share Forecast by Application (2023-2028)
Table 175. Global Antihypertensive Sales Forecast by Region (2023-2028) & (K Units)
Table 176. Global Antihypertensive Sales Market Share Forecast by Region (2023-2028)
Table 177. Global Antihypertensive Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 178. Global Antihypertensive Revenue Market Share Forecast by Region (2023-2028)
Table 179. Research Programs/Design for This Report
Table 180. Key Data Information from Secondary Sources
Table 181. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Antihypertensive
Figure 2. Global Antihypertensive Market Share by Type in 2021 & 2028
Figure 3. Diuretics Product Picture
Figure 4. Angiotensin Converting Enzyme (ACE) Inhibitors Product Picture
Figure 5. Angiotensin Receptor Blockers (ARBs) Product Picture
Figure 6. Calcium Channel Blockers Product Picture
Figure 7. Beta Blockers Product Picture
Figure 8. Alpha Blockers Product Picture
Figure 9. Vasodilators & Renin Inhibitors Product Picture
Figure 10. Global Antihypertensive Market Share by Application in 2021 & 2028
Figure 11. Hospital Pharmacy
Figure 12. Retail Pharmacy
Figure 13. Online Pharmacy
Figure 14. Others
Figure 15. Global Antihypertensive Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 16. Global Antihypertensive Market Size (2017-2028) & (US$ Million)
Figure 17. Global Antihypertensive Sales (2017-2028) & (K Units)
Figure 18. Antihypertensive Sales Share by Manufacturers in 2021
Figure 19. Global Antihypertensive Revenue Share by Manufacturers in 2021
Figure 20. The Global 5 and 10 Largest Antihypertensive Players: Market Share by Revenue in 2021
Figure 21. Antihypertensive Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 22. Global Antihypertensive Sales Market Share by Region (2017-2022)
Figure 23. Global Antihypertensive Sales Market Share by Region in 2021
Figure 24. Global Antihypertensive Revenue Market Share by Region (2017-2022)
Figure 25. Global Antihypertensive Revenue Market Share by Region in 2021
Figure 26. U.S. Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Canada Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. Germany Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. France Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. U.K. Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. Italy Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Russia Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. China Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Japan Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. South Korea Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. India Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Australia Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Taiwan Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Indonesia Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Thailand Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Malaysia Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Philippines Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Vietnam Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Mexico Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. Brazil Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 46. Argentina Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 47. Turkey Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 48. Saudi Arabia Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 49. U.A.E Antihypertensive Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 50. Sales Market Share of Antihypertensive by Type (2017-2022)
Figure 51. Manufacturing Cost Structure of Antihypertensive
Figure 52. Manufacturing Process Analysis of Antihypertensive
Figure 53. Antihypertensive Industrial Chain Analysis
Figure 54. Channels of Distribution
Figure 55. Distributors Profiles
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Pfizer Norvatis Merck & Co. Sanofi AstraZeneca GSK Daiichi-Sankyo Boehringer-Ingelheim Bayer Johnson & Johnson Bristol-Myers Squibb Tekeda Ranbaxy Laboratories Shihuida Pharm Second Pharmaceutical Lupin Limited. Yangtze River Pharmaceutical Hengrui Medicine Qilu Pharmaceutical HUALON Dawnrays HISUN Pharmceutical